VTRO (Vitro Biopharma) EBITDA Margin %: -191.62% (As of Oct. 2022)


What is Vitro Biopharma EBITDA Margin %?

Vitro Biopharma VTRO EBITDA Margin % is -191.62% as of Oct. 2022. The stock has 6 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vitro Biopharma's EBITDA for the three months ended in Oct. 2022 was $-6.31 Mil. Vitro Biopharma's Revenue for the three months ended in Oct. 2022 was $3.29 Mil. Therefore, Vitro Biopharma's EBITDA margin for the quarter that ended in Oct. 2022 was -191.62%.

Vitro Biopharma  (AMEX:VTRO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Vitro Biopharma EBITDA Margin % Related Terms

Vitro Biopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma EBITDA Margin % Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -106.99 -143.43 -112.98 -301.91 -191.62

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -106.99 -143.43 -112.98 -301.91 -191.62

VTRO vs : EBITDA Margin % Comparison

For the Biotechnology subindustry, Vitro Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitro Biopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vitro Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Vitro Biopharma's EBITDA Margin % falls into.


Vitro Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Vitro Biopharma's EBITDA Margin % for the fiscal year that ended in Oct. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Oct. 2022 )/Revenue (A: Oct. 2022 )
=-6.31/3.293
=-191.62 %

Vitro Biopharma's EBITDA Margin % for the quarter that ended in Oct. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Oct. 2022 )/Revenue (Q: Oct. 2022 )
=-6.31/3.293
=-191.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -191.62% mean?
Vitro Biopharma (VTRO) has a EBITDA Margin % of -191.62% as of Oct. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's EBITDA Margin % too high?
Vitro Biopharma's current EBITDA Margin % is -191.62%.
How does Vitro Biopharma's EBITDA Margin % compare to ?
Vitro Biopharma's EBITDA Margin % of -191.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current EBITDA Margin % is -191.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current EBITDA Margin % of -191.62%. The current EBITDA Margin % is -191.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current EBITDA Margin % is -191.62% as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.